Ref. No.P-66/2026-27/56
November 18th, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Dear Sir / Madam,

Sub: Intimation under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

This is to inform you that Coris Bioconcept SRL (hereinafter referred to as "Coris"), subsidiary of 3B BlackBio Dx Ltd. (hereinafter referred to as "3B") is pleased to announce that it has entered into a definitive agreement with Bilex SRL (hereinafter referred to as "Bilex") to acquire 100% shares of the company.

Bilex is the owner of land and building where the Coris office and manufacturing plant building is situated at Rue Guillaume Fouquet 11, 5032 Gembloux, Belgium. Coris shall acquire 100% of the total paid-up share capital of Bilex on November 18th 2026 from its shareholders Mr. Thierry Leclipteux and Mr. Joseph Bertinetti, and accordingly Bilex shall become a subsidiary of Coris as per the conditions set out in the Share Purchase agreement signed between the parties.

The details required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure I. A business update on the aforesaid acquisition is enclosed as Annexure II for your perusal and information.

Further, pursuant to Regulation 30 (8) of the SEBI LODR Regulations the enclosed disclosures and the business update are also made available on the company's website.

This is for your information and further dissemination.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

NIKHILKUBER DUBEY

Digitally signed by NIKHILKUBER DUBEY
Date: 2026.11.18 17:13:25 +05'30'

Nikhil Kuber Dubey
WholeTime Director
DIN: 00538049

Encl: As above

Annexure-I

Disclosure under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

S.No.	Particulars	Details
a)	Name of the Target Entity, details in Brief such as Size, Turnover etc.;	Bilex SRL, 11, Rue Guillaume Fouquet, 5032 Isnes (Gembloux) BELGIUM Turnover (Rental Income) - €227,319.00 (FY'24) €232,267.05 (FY'25)
b)	Whether the acquisition would fall within Related Party Transaction(s) and whether the Promoter/ Promoter Group/ Group Companies have any interest in the Entity being acquired? If Yes, nature of interest and details thereof and whether the same is done at "Arm's Length";	The acquisition does not fall within related party transactions. The promoter / promoter group have no interest in the entity being acquired.
c)	Industry to which the Entity being acquired belongs;	None – Owned/ Occupied Manufacturing Building being acquired.
d)	Objects and Impact of Acquisition (including but not limited to, Disclosure of Reasons for Acquisition of Target Entity, if its Business is outside the main line of Business of the listed entity);	1. At present, Coris is paying rent for the building. This acquisition transitions Coris BioConcept from a tenant to an owner-occupier. 2. By consolidating Bilex SRL accounts into Coris, intercompany rental payments will get eliminated. 3. The restructuring will generate an immediate net annual savings of €140,000 before depreciation. Moving forward, the only property-related expense reflected on the consolidated financial statements will be the direct bank interest paid on Bilex's long term loans apart from depreciation.
e)	Brief Details of any Governmental or Regulatory Approvals Required for the Acquisition;	None
f)	Indicative Time Period for Completion of the Acquisition;	Acquisition to be completed on 18/11/ 2026
g)	Consideration - Whether Cash Consideration or Share Swap or any Other Form and Details of the same;	€274,817 cash consideration for 100% shares of Bilex SRL along with payment of unsecured loan of €1.32 Million to two shareholders, and continuation of Bilex's long-term building loans of €2.11 Million at an attractive average interest rate of 1.3 % payable in remaining 12 years.
h)	Cost of Acquisition and/or the Price at Which the Shares are Acquired;	Acquisition of 100% shares of Bilex SRL will be acquired for €274,817.

<table>
<tr><td></td><td></td><td></td></tr>
<tr><td>i)</td><td>Percentage of Shareholding / Control Acquired and / or Number of Shares Acquired;</td><td>100% Equity Shares will be acquired by Coris from Bilex’s shareholders, Mr. Thierry Leclipteux(50%) and Mr. Joseph Bertinetti(50%).</td></tr>
<tr><td>j)</td><td>Brief Background about the Entity Acquired in terms of Products/Line of Business Acquired, Date of Incorporation, History of last 3 years turnover, Country in which the Acquired Entity has presence and any other Significant Information (in brief);</td><td>Bilex SRL, incorporated in 2014, which is the owner of land and building where Coris office and manufacturing plant is situated in Belgium. Following the closing of this transaction, Bilex SRL will operate as a wholly-owned subsidiary of Coris BioConcept.

This transaction aligns with Coris BioConcept's commitment to, long-term cost optimization, and securing the permanent infrastructure required to support its global diagnostic pipeline.

Details of Revenue:
<table>
<tr><th>Year</th><th>Approx. Revenue (Rental Income)</th></tr>
<tr><td>FY2023</td><td>€203,500.00</td></tr>
<tr><td>FY2024</td><td>€227,319.00</td></tr>
<tr><td>FY2025</td><td>€232,267.05</td></tr>
</table></td></tr>
</table>

Annexure –II

BUSINESS UPDATE: Coris BioConcept Announces Strategic Acquisition of 100% shareholding of Bilex SRL to Optimize Costs and Secure Facility Ownership

November 18th 2026, Gembloux, BELGIUM: Coris BioConcept SRL, a leading innovator in rapid diagnostic kits for AMR, today announced a strategic agreement to acquire 100% of the shares of Bilex SRL from existing shareholders Mr. Thierry Leclipteux and Mr. Joseph Bertinetti.

Bilex SRL is the owner of land and building where Coris office and manufacturing plant is situated. Following the closing of this transaction, Bilex SRL will operate as a wholly-owned subsidiary of Coris BioConcept. This corporate acquisition transitions Coris BioConcept from a tenant to an owner-occupier. By consolidating Bilex SRL into its corporate structure, intercompany rental payments will get eliminated.

This ultra-modern building was built in 2023 is located in the Créalys® Science Park Gembloux on a 6,443 m^2 land parcel. The building has a surface area of 2,000 m^2 which brings together the company's administrative, offices and labs. It includes state-of-the-art laboratories equipped with containment airlocks and temperature-controlled and humidity-controlled environments. These are essential to ensure that research conducted here is accurate and safe. This building is equipped with 256 solar panels, two 20,000-litre rainwater-collection tanks to supply the bathrooms, a thermodynamic tank and optimized insulation. These installations reflect the company's desire to minimize its environmental impact while continuing to develop.

The restructuring will generate an immediate net annual savings of €140,000 before depreciation. Moving forward, the only property-related expense reflected on the consolidated financial statements will be the direct bank interest paid on Bilex's existing long term building loans apart from depreciation.

This transaction aligns with Coris BioConcept's commitment to, long-term cost optimization, and securing the permanent infrastructure required to support its global diagnostic pipeline.

Mr. Sébastien Goenen (CEO – Coris Bioconcept SRL) said, "We are pleased to announce the acquisition of Bilex SRL. Transitioning from tenant to owner-occupier secures long-term control over our core operating infrastructure and delivers immediate, recurring savings to our cost base. Owning our Gembloux facility gives us the stability and flexibility to invest in our manufacturing capabilities and to scale operations in line with growing global demand for our rapid diagnostic solutions."

Mr. Dhirendra Dubey (Founder CEO – 3B BlackBio Dx Limited) said, "The acquisition of Bilex marks a prudent step in strengthening the operational foundation of Coris, our European subsidiary and a recognized leader in lateral flow assay technology for antimicrobial resistance (AMR) diagnostics. Securing ownership of its Gembloux headquarters and manufacturing facility optimizes its rental outflows, and is expected to provide long-term certainty over a critical operating asset."

About 3B BlackBio Dx Limited:

3B is a research-driven company dedicated to the development, validation, and manufacturing of high-quality *in vitro* diagnostic (IVD) products. Under its brands, TRUPCR®, TRURAPID®, and TRUNGS®. **3B** offers a comprehensive portfolio focused on oncology and infectious disease diagnostics.

With over 14 years of industry expertise and more than 100 successfully launched products, 3B is committed to advancing patient care through innovative and reliable diagnostic solutions. All molecular diagnostic kits are developed and manufactured in compliance with the highest quality standards, backed by ISO 13485:2016 certification through BSI, UK.

About Coris Bioconcept SRL:

Founded in 1996 and headquartered in Gembloux, Belgium, **Coris** develops, manufactures and distributes i*n vitro* diagnostic (IVD) rapid test kits, with a primary focus on lateral flow assays designed for use by healthcare professionals.

Coris is ISO 13485 certified, ensuring the highest standards of quality and regulatory compliance across its operations. The company distributes its products through a global network of distributors in over 60 countries, reaching markets in Europe, Asia, South America, Africa, and Oceania.



Image – Coris Building at Gembloux.